LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Laboratories Showcases Advances in Biotechnology at Clinical Lab Expo

By LabMedica International staff writers
Posted on 01 Aug 2018
Print article
Image: At AACC 2018, Randox highlighted a wide range of its testing products and biotech advances (Photo courtesy of Randox Laboratories).
Image: At AACC 2018, Randox highlighted a wide range of its testing products and biotech advances (Photo courtesy of Randox Laboratories).
Randox Laboratories (Crumlin, UK), one of the world’s leading medical diagnostics manufacturer, showcased advancements in biotechnology at AACC 2018, the world’s largest diagnostics conference, held in Chicago, Illinois, from the July 29 – August 2.

The American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, considered to be the leading event for laboratory medicine worldwide, offered Randox the opportunity to showcase its capabilities to more than 20,000 healthcare professionals and decision makers from around the globe.

At AACC 2018, Randox hosted demonstrations of a wide range of its intuitive multiplex analyzers, including the Randox Evidence Evolution, which is the world’s first fully automated random access testing platform that is capable of delivering 2,640 results in one hour, with the first results delivered in only 37 minutes. The Randox Evidence Evolution runs on the company’s patented Biochip Array Technology, which can currently run 49 different tests simultaneously, ensuring fast, accurate and reliable diagnosis.

Randox also launched a number of new tests on the Randox Biochip at this year’s AACC event, including a diagnostic test for the differentiation of hemorrhagic and ischemic strokes, an algorithm capable of generating a patient’s Type 1 Diabetes Genetic Risk Score, and a test to diagnose Acute Kidney Injury (AKI) in participants of pharmaceutical drug trials.

“Our pioneering diagnostic technologies are leading the way in innovation and have real potential to transform healthcare around the world. We remain committed to developing new health diagnostic technologies for a range of the world’s most pressing health issues in need of the most urgent address, and to expanding the business in our key markets, such as the US,” said Randox managing director, Dr. Peter FitzGerald. “Our very significant investment in research and development means that we have more new tests in development than any other healthcare company in the world and are able each year to bring a wealth of exciting new technologies to the American market.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more